Introduction
Opiate substitution treatment (OST) has recently been shown to achieve similar positive outcomes in numerous countries with incomes ranging from low to high. Outcomes include the reduction of heroin and other illicit opiate use, the reduction of HIV exposure-risk behaviors associated with injection drug use, the decrease of criminal activities and the improvement of physical and mental health [1] . As part of this international study a first feasibility study was performed in Ukraine, whose 12-month treatment data will be described in detail in the current report.
According to a recent WHO estimation [2, 3] there are between 325,000 and 425,000 injection drug users (IDUs) in Ukraine, of whom 144,000 are estimated to be HIV positive. To our knowledge, there are currently no estimations or exact numbers for the mortality rate among IDUs.
Despite this high prevalence of IDUs, until 2004 drug treatment programs relied on detoxification and abstinence-based rehabilitation in so called 'narcological centers' [4] . Because of political and clinical mistrust of OST, buprenorphine was the only medication available for OST between 2004 and 2007 . With the collaboration of the World Health Organization (regional office for Europe), the International HIV/AIDS Alliance, the Ukrainian Institute for Public Health Policy and the management and staff of existing treatment sites, the implementation of 6 buprenorphine maintenance treatment (BMT) sites started at the beginning of 2006. In June 2007, methadone was approved by the Ukrainian Ministry of Health and will now also be made available for maintenance treatment. Nevertheless, the number of IDUs receiving agonist maintenance is still very low and the vast majority of IDUs have not yet been reached by OST [4] .
There are several specific aspects of opioid use patterns in the Ukraine that have to be kept in mind. Most Ukrainian IDUs do not use heroin but a self-made opioid called 'shirka', which is prepared from poppy straw in a common container shared among several users. A contaminated needle can result in contaminating the whole shirka and infecting other users. Also, ready-made shirka is available in preloaded unsterile syringes. These tend to be re-used and carry a high risk for contamination as they have usually been already used by the drug dealers themselves [5, 6] .
In addition to the low availability of agonist maintenance in the Ukraine, access to antiretroviral therapy (ART) for IDUs was and still is low, and clinicians have tended to refuse ARTs to active IDUs, believing that they would be poorly adherent [4] . However, recent evidence has emerged that integrating ART and OST in HIV-positive IDUs can optimize outcomes for both opiate addiction and HIV infection status [7] .
This publication reports the first year treatment data of the first 6 buprenorphine treatment sites in the Ukraine (Kiev City AIDS center and Sociotherapy clinic, Donetsk Narcological Dispensary, Odessa Oblast Narcological Dispensary, AR Crimea Republican Narcological Dispensary, Dnijpropetrovsk Narcological Dispensary and Mykolaiv Narcological Dispensary). More precisely, it focuses on the description of the outcomes of opiate-dependent patients in this BMT program at baseline and at 6-and 12-month follow-up.
Methods

Study Population
Since BMT started in 6 already existing treatment places, patients were asked if they were willing to start a BMT during a recruitment period of 2-3 months. At the beginning of the recruitment, this new treatment possibility was demanded by almost every patient (n = 176). A patient recruitment list was prepared for documenting the basic characteristics of persons applying for OST at the sites, for documenting their eligibility and their eventual admittance to the program by treatment staff at their sites. Patients with signs of severe cognitive impairment, mental retardation, severe behavior disturbances or psychotic symptoms were excluded from the study. Furthermore, patients who were expecting hospitalization or imprisonment were also excluded. In order to be eligible for participation in the study, patients had to fulfil dependence diagnosis for opiates according to ICD-10, be at least 18 years old, be living in permanent residence within commuting distance of the respective OST clinic and provide informed consent to treatment and the treatment regime, including blood testing, and to their participation in the study follow-up interviews. 153 eligible patients were recruited for the OST program and the study. Only 2 patients refused to give informed consent. Finally, a total of 151 patients were included in the study.
Patients had to ingest their individual dose of buprenorphine at the OST site on a daily basis. According to the Ukrainian guidelines for good practice in BMT, higher buprenorphine doses were prescribed at the beginning of treatment to suppress withdrawal syndromes (typically 12-14 mg). The doses were then gradually reduced to the maintenance dose, which usually was from 2 to 8 mg. For the most part, this was on the initiative of the patients, who usually had plans to leave the program in the long run due to the inconvenience of coming each day to be supervised while they took the BMT. Patients were also tested for HIV in the first 2 weeks of the BMT study. Hepatitis B and C status were taken from the medical records at the beginning of the study. Care was provided to seropositive patients outside the OST sites by AIDS centres (further HIV testing, laboratory monitoring and ART provision). All OST and HIV/AIDS services were free of charge.
Treatment Staff and Monitoring
At all sites, relevant professionals (doctors, psychiatrists, nurses, psychologists, and social workers) were in the team taking care of the somatic, psychiatric, psychological and social needs of patients. In all teams at all project sites, competence to work with drug-dependent persons was assured by recurring training according to the Ukrainian guidelines for good practice in BMT, as well as by supervision on request. The monitoring and evaluation protocol and plan was developed at the Research Institute for Public Health and Addiction at Zurich University, in consultation with the WHO Euro-office, the International HIV/AIDS Alliance, the OST program managers and the Ukrainian Institute of Public Health Policy. An international consultant from Vilnius University visited all OST sites.
Data Collection
Patient descriptions, baseline and follow-up data (6 and 12 months after intake) were collected by use of a clinical record form. An external interviewer assessed history and patterns of substance use with the Addiction Severity Index (ASI) [8] at baseline and follow-up. Furthermore, the external interviewer administered the Blood-Borne Virus Transmission Risk Assessment Questionnaire BBV-TRAQ [9] at baseline and follow-up to determine risk behaviors. The Ukrainian Institute of Public Health Policy translated both questionnaires into Ukrainian. Data on status, regime, treatment received, adverse events, compliance and termination were entered daily by OST treatment staff into 159 standardized patient records prepared by the same institute. Patients who dropped out of the study were contacted if possible in order to find out more about their reasons for dropping out and to motivate them to participate in the nearest follow-up interview. Reasons for dropout were noted on the patients' clinical report forms.
Data Management and Analyses
Data were transmitted electronically to the Ukrainian Institute of Public Health Policy and entered into a relational database. All patient data were coded and recorded anonymously. Differences between baseline and follow-up data were tested by repeated-measures analysis of variance test statistic for those patients who stayed in treatment. In case of categorical variables, applicable data percentages were specified and 2 tests for dependent and independent samples were applied, respectively. The reasons why patients dropped out of the study were reported on the clinical report form. Finally, a Cox regression analysis for months in treatment was performed to investigate effects of baseline characteristics, mean buprenorphine dose, baseline HIV status, and baseline ASI and BBV-TRAQ scores as predictors. Dropouts' baseline data were further compared with baseline data of those patients who reached the 12 month follow-up. P ! 0.05 was considered statistically significant. All data were analyzed with the statistical software package SPSS, version 15.
Results
Sample Characteristics
A total of 151 BMT patients entered the study at baseline. Seventy-five percent of all patients were male, had an average age of 35.2 ( 8 7.7), declared on average 10.8 ( 8 2.0) years of education and 1.8 ( 8 1.9) years of professional education. More than half of all patients were married (54.3%), only 4.6% stated they lived in irregular housing conditions (homeless) and 38.1% stated they held a legally paid job. By far the longest history of substance use related to 'other opiates' (13.5 8 7.6 years), followed by cannabis use (6.6 8 8.8 years) and polydrug use (6.0 8 6.3 years). In contrast, the use of other substances, and especially of heroin, was more recent. Barbiturate use went back 1.4 8 3.0 years and the use of sedatives and tranquillizers 2.7 8 4.5 years. Accordingly, the range of drug use history was greatest between use of other opiates (almost exclusively shirka) and use of heroin.
The large majority of former treatments received were for drug problems, with an average of 5.6 ( 8 7.8) treatments per patient. Previous treatments for alcohol problems (0.1 8 0.6 episodes) and psychiatric problems (0.3 8 0.9 episodes) were much less frequent. 75.3% of all patients had been arrested at least once. 15.2% of all patients had been participating in groups of Alcoholics Anonymous or Narcotics Anonymous.
More than half of all patients (51.7%) were found to be HIV positive at entry into the program. In regard to the infection stage, clinical AIDS syndrome was diagnosed in 12.3% of the HIV infected patients at baseline. Hepatitis C virus seropositivity was reported in 15.8% (17.2% missing) of patients and the rate for hepatitis B seropositivity was 3.3% (17.2% missing). There was a deficit in tuberculosis diagnosis (9.5% were tuberculosis positive but data were missing in 62.9% of patients). 
Treatment Outcomes
Dropouts
A total of 22 (14.6%) patients dropped out of the study after the 6-month follow-up and an additional 9 (5.9%) patients dropped out after the 12-month follow-up. Reasons for these 33 (20.5%) dropouts were: systematic nonattendance and intake of illegal drugs (11 patients); imprisonment (6 patients); treatment regime violation (2 patients); absence of euphoric sensations so the patient wished to stop treatment (8 patients); move to a '12-step' rehabilitation program (1 patient), move to religious rehabilitation center (1 patient); admission to hospital (1 patient); move to another city (1 patient); unknown (1 patient), and hospitalization followed by death in hospital (1 patient). None of the dropout patients could be motivated for the next follow-up interview.
The Cox regression for month in treatment ( 2 148; 23 = 33.641, n.s.) revealed no significant effects on patients who dropped out for the covariates age, sex, age of first 
Discussion
The study outcomes during the 12 months of treatment were impressive. There were large reductions in use of illegal and non-prescribed substances, illegal activities, illegal incomes and risk-taking behaviors. Patients' employment rates increased and their psychiatric problems improved.
It also revealed that the target group of chronic Ukrainian opiate (shirka) users, who were relapsing after many previous drug-free treatments, were willing to enter OST and that the great majority remained in treatment during a 1-year observation period. This study also documented that almost all patients gave their consent to participate in an extensive data collection used for evaluation purposes. Getting their medication at the OST sites by daily supervised intake restricted their freedom to work and relaxation during weekends and vacations.
The reason why one fifth of patients dropped out of the study could be ascribed to the usual dropout reasons for these types of studies (systematic non-attendance and intake of illegal drugs, absence of euphoric sensations and therefore the patient wishing to stop treatment) for patients who tended to carry a higher burden of drug, family and psychiatric problems at baseline. However, these dropout rates could also have emerged from specific Ukrainian OST prescription regulation problems (some patients had to be admitted to hospital, or were imprisoned within the 12 months, although patients who were expecting hospitalization or imprisonment were excluded from the study at baseline).
Thus, one of the biggest obstacles that emerged during the study period was that OST could not be continued for patients who had to be hospitalized. Hospitals had no license to store controlled medications. Likewise, imprisonments lead to interruption of substitution treatment. Another problem that emerged during the study was that although the provision of ART medication for HIV-positive patients at the AIDS centers increased during the 12 months, we must assume that not all patients who would profit from ART medication actually received it.
The main strength of the current study is that it provides the first systematically collected data on the feasibility of OST in Ukraine and in a comparatively large sample of specific homemade opiate (shirka) injectors. However, there are also some limitations to the current study: (1) it had to rely on self-declaration when assessing frequency of substance use, since systematic urine testing would have been too expensive; (2) patients were recruited within already existing (previously abstinence-oriented) treatment places what could have led to a selection bias; (3) there were some language restrictions (e.g. the ASI and the BBV-TRAQ had to be translated into Ukrainian but could not be validated as part of the current study).
In consideration of the current study results, we conclude that a successful and adequate implementation of OST in the Ukraine is feasible. Scale-up of OST in the Ukraine is highly recommended.
